service agreement between Solvay and AGC, plus higher transportation costs from export sales portion. 3. In Q2 2017, the Company and its subsidiaries recorded additional impairment loss from the liquidation
Expenses was 334 MB, increased by 74 MB or 28.4% comparing to 2016 due to related expenses of the transitional service agreement between Solvay and AGC, plus higher transportation and commission costs from
impairment loss from the liquidation of Solvay Biochemicals (Taixing) Limited (“SBT”) were fully booked in 2017. * Note Please find further information in the consolidated financial statements. 2 Summary of
the liquidation of Solvay Biochemicals (Taixing) Limited were fully booked in 2017. 4. 93 MB loss on dilution on investment in an associate was recorded from the change in the Company’s ownership
good corporate governance practices, the following directors who are representatives of Solvay S.A. did not attend the Board of Directors Meeting for this specific matter and had no right to vote. 1) Mr
of Solvay Biochemicals (Taixing) Limited (“SBT”) in 2017. 3. In 2018, the Company and its subsidiaries recorded loss on dilution on investment in Pimai Salt Company Limited amounting to 32 MB from the
on dissolution of Solvay Biochemicals (Taixing) Limited amounting to 89 MB from other comprehensive income to the profit of the year 2018. Summary of Performance For the year 2019, the Company and its
expenses was 1,719 MTHB, increased by 546 MTHB or 47% from 2016. This increment was mainly from the loss on written-off and disposal of plant and equipments and intangible assets of Solvay Biochemicals
, Belgian company, who is an subsidiary of Vinythai, due to practical difficulties to maintain company operation after the expiration of service agreement provided to it by Solvay SA (the former major